| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |